Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity (vol 117, 105447, 2021)

被引：0
|
作者：
Li, Ling [1 ]
Wu, Yinrong [1 ]
Yang, Zichao [1 ]
Xu, Chenglong [1 ]
Zhao, Huiting [1 ]
Liu, Jin [1 ]
Chen, Jingxuan [1 ]
Chen, Jianjun [1 ]
机构：
[1] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China
来源：
BIOORGANIC CHEMISTRY | 2024年 / 150卷
关键词：
D O I：
10.1016/j.bioorg.2024.107616
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Discovery and characterization of ABSK071, a novel and potent small-molecule covalent inhibitor for KRAS-G12C
    Guo, F.
    Zhao, Y.
    Yu, H.
    Xu, Y.
    Chen, Z.
    Yang, S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S22 - S23
  • [42] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [43] PI3K pathway inhibition induces a different metabolic response in NSCLC cells harboring and G12C mutant KRAS
    Caiola, Elisa
    Brunelli, Laura
    Marabese, Mirko
    Pastorelli, Roberta
    Lupi, Monica
    Broggini, Massimo
    CANCER RESEARCH, 2016, 76
  • [44] Discovery of novel potent allele-selective KRAS-G12C covalent inhibitors stemming from DNA-encoded library
    McCort, Gary
    Arrebola, Rosalia
    Calvet, Loreley
    Ronan, Baptiste
    Vergne, Fabrice
    Duffieux, Francis
    Rak, Alexey
    Meaux, Isabelle
    Papin, David
    Fassy, Florence
    Delorme, Cecile
    Matthieu, Magali
    Nicolas, Jean-Paul
    Marcireau, Christophe
    Steier, Valerie
    Abecassis, Pierre-Yves
    Czepczor, Valerie
    Thomson, Heather A.
    Hupp, Christopher D.
    Guilinger, J. P.
    Zhang, Ying
    Keefe, Anthony D.
    Cuozzo, John W.
    Liu, Julie
    Debussche, Laurent
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization
    Shi, Jian-Tao
    Hou, Su-Juan
    Cheng, Lei
    Zhang, Hao-Jie
    Mu, Hong-Xia
    Wang, Qing-Shan
    Wang, Zhao-yang
    Chen, Shi-Wu
    BIOORGANIC CHEMISTRY, 2024, 148
  • [46] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [47] Characterizing the KRAS G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas
    Li, Meredith
    Keshavarz-Rahaghi, Faeze
    Ladua, Gale
    Swanson, Lucas
    Speers, Caroline
    Renouf, Daniel J.
    Lim, Howard J.
    Davies, Janine M.
    Gill, Sharlene
    Stuart, Heather C.
    Yip, Stephen
    Loree, Jonathan M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [48] Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
    Caiola, Elisa
    Brunelli, Laura
    Marabese, Mirko
    Broggini, Massimo
    Lupi, Monica
    Pastorelli, Roberta
    ONCOTARGET, 2016, 7 (32) : 51462 - 51472
  • [49] Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-like KRAS G12C Inhibitors (vol 9, pg 51508, 2024)
    Frommlet, Alexandra
    Nguyen, Lan K.
    Saabye, Matt
    Endres, Nicholas F.
    Mulvihill, Melinda M.
    Quinn, John G.
    ACS OMEGA, 2025, 10 (11): : 11642 - 11642
  • [50] A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
    Wu, Lisha
    Xu, Maosheng
    Li, Xueqin
    Aierken, Dilinuer
    Yu, Jinxiu
    Qin, Tao
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345